NYSE: RBOTVicarious Surgical Inc Stock
$7.36+0.03 (+0.41%)
Updated Jul 2, 2025
RBOT Price
$7.36
Fair Value Price
N/A
Market Cap
$43.66M
52 Week Low
$4.27
52 Week High
$19.00
P/E
-0.7x
P/B
1.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.62
Operating Cash Flow
-$47M
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RBOT Overview
Vicarious Surgical Inc. is a robotics company developing human-like surgical robots and a virtual reality platgform that "transports" surgeons inside the patient for minimally invasive surgery. The company combines miniaturized robotics, computer science, and 3D visualization to build single-incision surgical robots called the Vicarious System. Vicarious Surgical was incorporated in 2014 and is headquartered in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RBOT's potential to beat the market
- RBOT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
RBOT
RankedUnranked of 105
RankedUnranked of 105
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.38 | A | |
| $30.16 | A | |
| $238.25 | A |
Be the first to know about important RBOT news, forecast changes, insider trades & much more!
RBOT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RBOT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RBOT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RBOT is good value based on its book value relative to its share price (1.28x), compared to the US Medical Devices industry average (4.09x)
P/B vs Industry Valuation
RBOT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RBOT due diligence checks available for Premium users.
Valuation
RBOT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.7x
Industry
36.04x
Market
31.27x
RBOT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.28x
Industry
4.09x
RBOT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RBOT's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.4M
Profit Margin
0%
RBOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$55.1M
Liabilities
$21.0M
Debt to equity
0.62
RBOT's short-term assets ($39.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RBOT's short-term assets ($39.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RBOT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.8M
Investing
$4.6M
Financing
$17.0k
RBOT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RBOT vs Medical Device Stocks
Vicarious Surgical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.